Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press51010.17650/2686-9594-2021-11-2-49-54LITERATURE REVIEWОБЗОР ЛИТЕРАТУРЫCervical cancer in the Russian Federation and the risks of vaginal fistulaРак шейки матки в РФ и риски формирования вагинальных свищейSaryevM. N.СарыевМ. Н.
Russian Federation

Mukhammetsakhet Nurberdievich Saryev

4 Kashirskoe Shosse, Moscow 115478

Мухамметсахет Нурбердиевич

115478 Москва, Каширское шоссе, 24

mishamoff@gmail.comValievR. K.ВалиевР. К.
Russian Federation

86 Shosse Entuziastov, Moscow 111123

111123 Москва, шоссе Энтузиастов, 86

NechushkinM. I.НечушкинМ. И.
Russian Federation

4 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

NurberdyevM. B.НурбердыевМ. Б.
Russian Federation

86 Shosse Entuziastov, Moscow 111123

111123 Москва, шоссе Энтузиастов, 86

PanichenkoI. V.ПаниченкоИ. В.
Russian Federation

4 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

TizilovaE. A.ТизиловаЕ. А.
Russian Federation

4 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава РоссииA.S. Loginov Moscow Clinical Scientific Center of the Moscow Healthcare DepartmentГБУЗ г. Москвы «Московский клинический научно-практический центр им. А. С. Логинова Департамента здравоохранения г. Москвы2811202111249542811202128112021Copyright ©; 2021, ABV-pressCopyright ©; 2021, АБВ-пресс2021ABV-pressАБВ-прессhttps://onco-surgery.info/jour/about/editorialPolicieshttps://onco-surgery.info/jour/article/view/510

This review aims to provide up-to-date information on the factors associated with an increased risk of vaginal fistula in women with cervical cancer, as well as on methods of their prevention and treatment. It includes data on various types of vaginal fistulas in cervical cancer patients and risk factors for their development, according to foreign and Russian research articles published over the last 20 years. Cervical cancer is one of the most challenging oncological diseases in the Russian Federation, because it is detected at stage III–IV in more than 30 % of women. Such a high incidence of cervical cancer and the need for radiotherapy determine high risk of fistulas, which significantly impairs the quality of life. Thus, identification of factors associated with vaginal fistulas, as well as methods of their prevention and treatment remains a highly relevant task for the Russian healthcare system.

Целью работы является предоставление актуальной информации о факторах, ассоциированных с развитием вагинальных свищей на фоне рака шейки матки, а также о методах их профилактики и лечения. Обзор содержит данные о различных видах вагинальных свищей у больных раком шейки матки и факторах риска формирования свищей, полученные из зарубежных и российских научных статей по теме, опубликованных за последние 20 лет. Рак шейки матки для нашей страны является одной из значимых онкологических патологий, так как заболевание выявляется на III–IV стадии более чем у 30 % женщин. Такое распространение само по себе, как и необходимость проведения лучевой терапии, определяет высокий риск развития свищей, что значимо ухудшает качество жизни пациенток. Следовательно, поиск факторов, ассоциированных с развитием вагинальных свищей, а также методов профилактики и лечения – по-прежнему актуальная задача для нашей страны.

cervical cancervaginal fistulaurogenital fistularectovaginal fistulaрак шейки маткивагинальные свищиурогенитальные свищиректовагинальные свищиWHO Handbook for health inequality monitoring. Available at: https://www.who.int/gho/health_equity/handbook/en/.Malignant tumors in Russia in 2019. (incidence and mortality). Ed. by A.D. Kaprin, V.V. Starinskiy, A.O. Shakhzodova. Moscow: P.A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Research Center of Radiology, Ministry of Health of Russia, 2020. 252 p. (In Russ.).Злокачественные новообразования в России в 2019 г. (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 252 с.Situation with cancer care in Russia in 2019. Ed. by A.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: P.A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Research Center of Radiology, Ministry of Health of Russia, 2020. 239 p. (In Russ.).Состояние онкологической помощи населению России в 2019 г. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 239 с.Lind H., Waldenstrom A.C., Dunberger G. et al. Late symptoms in long-term gynaecological cancer survivors after radiation therapy: a population-based cohort study. Br J Cancer 2011;105:737Y745. DOI: 10.1038/bjc.2011.315.Kirwan J.M., Symonds P., Green J.A. et al. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol 2003;68:217Y226. DOI: 10.1016/s0167-8140(03)00197-x.Baalbergen A., Veenstra Y., Stalpers L. Primary surgery versus primary radiotherapy with or without chemotherapy for early adenocarcinoma of the uterine cervix. Cochrane Database Syst Rev 2013;1:CD006248YCD006248.Lanceley A., Fiander A., McCormack M. et al. Follow-up protocols for women with cervical cancer after primary treatment. Cochrane Database Syst Rev 2013;11:CD008767YCD008767.Wilson S.M., Sikkema K.J., Watt M.H. et al. Psychological symptoms among obstetric fistula patients compared to gynecology outpatients in Tanzania. Int J Behav Med 2015;22:605–13.Vangeenderhuysen C., Prual A., Ouldel Joud D. Obstetric fistulae: incidence estimates for subSaharan Africa. Int J Gynaecol Obstet 2001;73:65–6.Trovik J., Thornhill H.F., Kiserud T. Incidence of obstetric fistula in Norway: a population-based prospective cohort study. Acta Obstet Gynecol Scand 2016;95:405–10.Brown H.W., Wang L., Bunker C.H. et al. Lower reproductive tract fistula repairs in inpatient US women, 1979–2006. Int Urogynecol J Pelvic Floor Dysfunct 2012;23:403–10. DOI: 10.1007/s00192-011-1653-3.Børseth K.F., Acharya G., Kiserud T. et al. Incidence of gynecological fistula and its surgical treatment: A national registrybased study. Acta Obstet Gynecol Scand 2019;98:1120–6.Virdee N.K., Ringdal E.K., Thornhill H. et al. Gynaecological fistulae after surgery or radiotherapy. Tidsskr Nor Laegeforen 2020;140(12). DOI: 10.4045/tidsskr.19.0822.Hilton P. Urogenital fistula in the UK: a personal case series managed over 25 years. BJU Int 2012;110:102–10.Turina M., Mulhall A.M., Mahid S.S. et al. Frequency and surgical management of chronic complications related to pelvic radiation. Arch Surg 2008;143:46–52, discussion 52. DOI: 10.1001/archsurg.2007.7.Allanson E.R., Powell A., Bulsara M. et al. Morbidity after surgical management of cervical cancer in low and middle income countries: A systematic review and metaanalysis. PLoS One 2019;14(7):e0217775.Hilton P., Cromwell D.A. The risk of vesicovaginal and urethrovaginal fistula after hysterectomy performed in the English National Health Service – a retrospective cohort study examining patterns of care between 2000 and 2008. BJOG 2012;119:1447–54. DOI: 10.1111/j.1471-0528.2012.03474.x.Aarts J.W., Nieboer T.E., Johnson N. et al. Surgical approach to hysterectomy for benign gynaecological disease. Cochrane Database Syst Rev 2015;8:CD003677.Emmert C., Kohler U. Management of genital fistulas in patients with cervical cancer. Arch Gynecol Obstet 1996;259:19Y24.Welk B., Wallis C., D’Souza D. et al. A population-based assessment of urologic procedures and operations after surgery or pelvic radiation for cervical cancer. Int J Gynecol Cancer 2018;28(5):989–95.Fujikawa K., Miyamoto T., Ihara Y. et al. High incidence of severe urologic complications following radiotherapy for cervical cancer in Japanese women. Gynecol Oncol 2001;80:21Y23. DOI: 10.1006/gyno.2000.6030.Tzu-Chi H., Ting-Ming H., Yuh-Cheng Y. et al. A surgeon’s help with the management of bowel problems related to gynecology is truly needed – comparison of two periods spanning 24 years. Taiwan J Obstet Gynecol 2012;51(4):612–5.Riss P., Neunteuful W., Janish H. Wertheim radical hysterectomy 1921– 1986: changes in urologic complications. Arch Gynecol Obstet 1988;243:249–53.Timmer P.R., Aalders J.G., Bouma J. Radical surgery after preoperative intracavitary radiotherapy for stage IB and IIA carcinoma of the uterine cervix. Gynecol Oncol 1984;18:206–12.Lee Y.-N., Wang K.L., Lin M.-H. Radical hysterectomy with pelvic lymph node dissection for treatment of cervical cancer: a clinical review of 954 cases. Gynecol Oncol 1989;32:135–42.Abrão F.S., Breitbarg R.C., Oliveira A.T., Vasconcelos F.A. Complications of surgical treatment of cervical carcinoma. Brazil J Med Biol Res 1997;30:29–33.Falk V., Lundgren N., Quarfordt L., Arstrom K. Primary surgical treatment of carcinoma stage I of the uterine cervix. Acta Obstetrica et Gynaecologica Scandinavica 1982;61:481–6. DOI: 10.3109/00016348209156596.Novak F. Procedure for the reduction of the number of ureter-vaginal fistulas after Wertheim’s operation. Am J Obstet Gynecol 1956;72:506–10.Lanowska M., Brink-Spalink V., Mangler M. et al. Vaginal-assisted laparoscopic radical hysterectomy (VALRH) versus laparoscopic-assisted radical vaginal hysterectomy (LARVH) in the treatment of cervical cancer: surgical results and oncologic outcome. Arch Gynecol Obstet 2014;289(6):1293–300.Naik R., Jackson K.S., Lopes A. et al. Laparoscopic-assisted radical vagina hysterectomy versus radical abdominal hysterectomy – a randomized phase II trial: perioperative outcomes and surgicopathological measurements. BJOG 2010;117(6):746–51.Angioli R., Penalver M., Muzii L. et al. Guidelines of how to manage vesicovaginal fistula. Crit Rev Oncol Hematol 2003;48(3):295–304.Moore K.N., Gold M.A., McMeekin D.S., Zorn K.K. Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma. Gynecol Oncol 2007;106(3):498–501. DOI: 10.1016/j.ygyno.2007.04.030.Biewenga P., Mutsaerts M.A., Stalpers L.J. et al. Can we predict vesicovaginal or rectovaginal fistula formation in patients with stage IVA cervical cancer? Int J Gynecol Cancer 2010;20(3):471–5.Syed A.M., Puthawala A.A., Abdelaziz N.N. et al. Longterm results of low-dose-rate interstitial-intracavitary brachytherapy in the treatment of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2002;54(1):67–78.Pisani P., Bray F., Parkin D.M. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002;97:72Y81.Quinn M.A., Benedet J.L., Odicino F. et al. Carcinoma of the cervix uteri. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006;95:S43YS103.Quinn M.A., Benedet J.L., Odicino F. et al. Carcinoma of the cervix uteri. FIGO 6th annual report on the results of treatment in gynecological cancer 2. Int J Gynaecol Obstet 2006;95:S43YS103. DOI: 10.1016/S0020-7292(06)60030-1.Monk B.J., Tewari K.S., Koh W.J. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol 2007;25:2952Y2965.Kramer C., Peschel R.E., Goldberg N. et al. Radiation treatment of FIGO stage IVA carcinoma of the cervix. Gynecol Oncol 1989;32:323Y326.De Wilt J.H., van Leeuwen D.H., Logmans A. et al. Pelvic exenteration for primary and recurrent gynaecological malignancies. Eur J Obstet Gynecol Reprod Biol 2007;134:243Y248.Marnitz S., Kohler C., Muller M. et al. Indications for primary and secondary exenterations in patients with cervical cancer. Gynecol Oncol 2006;103:1023Y1030.Ungar L., Palfalvi L., Novak Z. Primary pelvic exenteration in cervical cancer patients. Gynecol Oncol 2008;111:S9YS12.8Y10.Tewari K.S., Sill M.W., Penson R.T. et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynaecologic Oncology Group 240). Lancet 2017;390:1654–63.Sturdza A., Hofmann S., Polterauer S. et al. Increased genitourinary fistula rate after Bevacizumab in recurrent cervical cancer patients initially treated with definitive radiochemotherapy and imageguided adaptive brachitherapy. Strahlenther Onkol 2017;193:1056–65. DOI: 10.1007/s00066-017-1178-x.Tognarelli A., Faggioni L., Manassero F. et al. A case report of endorectal displacement of a right ureteral stent following radiochemotherapy and Bevacizumab. BMC Urol 2019;19(1):128.Likić-Ladević I., Kadija S., Ladević N. et al. Urological complications after radical hysterectomy: incidence rates and predisposing factors. Vojnosanit Pregl 2007;64(6):381–4.Sun R., Koubaa I., Limkin E.J. et al. Locally advanced cervical cancer with bladder invasion: clinical outcomes and predictive factors for vesicovaginal fistulae. Oncotarget 2018;9(10):9299–310.Kasibhatla M., Clough R.W., Montana G.S. et al. Predictors of severe gastrointestinal toxicity after external beam radiotherapy and interstitial brachytherapy for advanced or recurrent gynecologic malignancies. Int J Radiat Oncol Biol Phys 2006;65(2):398–403.Ampuero F., Doss L.L., Khan M. et al. The Syed-Neblett interstitial template in locally advanced gynecological malignancies. Int J Radiat Oncol Biol Phys 1983;9:1897–903.Hata M., Koike I., Miyagi E. et al. Radiation therapy for stage IVA uterine cervical cancer: treatment outcomes including prognostic factors and risk of vesicovaginal and rectovaginal fistulas. Oncotarget 2017;8(68):112855–66. DOI: 10.18632/oncotarget.22836.Shevchuk A.S., Payanidi Yu.G., Afanasyeva K.V. Staging of gynecological cancers in the Russian Federation. Onkoginekologiya = Gynecologic Oncology 2020:69–77. (In Russ.).Шевчук А.С., Паяниди Ю.Г., Афанасьева К.В. Cтадирование онкогинекологических заболеваний в Российской Федерации. Онкогинекология 2020:69– 77.